Huiqiong Zeng

Dr. Huiqiong Zeng


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
HZHuiqiong Zeng
Huiqiong Zeng
BLBaiwei Luo
Baiwei Luo
YZYue Zhang
Yue Zhang
ZXZhongyu Xie
Zhongyu Xie
ZYZhizhong Ye
Zhizhong Ye
The pathogenesis of reactive arthritis (ReA) has not been fully elucidated. In recent years, many researchers have confirmed that multiple cytokines are involved in the occurrence and development of ReA. Although ReA is self-limiting, it is still incurable for some patients who have no or a weak response to traditional drugs, such as non-steroidal anti-inflammatory agents, glucocorticoids and immunosuppressive agents. This is called refractory reactive arthritis. Currently, there is insufficient evidences for the treatment of refractory ReA with biological agents, though biological agents against cytokines have been developed over the past few years. This review summarizes the current development of clinical treatments of ReA with biological agents, which provides future investigations on refractory ReA with more evidence and references.

2 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
BLBaiwei Luo
Baiwei Luo
KZKaixia Zhou
Kaixia Zhou
YLYingcong Liufu
Yingcong Liufu
XHXia Huang
Xia Huang
HZHuiqiong Zeng
Huiqiong Zeng
ZZZhaoyang Zhang
Zhaoyang Zhang
MicroRNAs(miRNAs) have emerged as key regulators that control and influence gene expression as well as multiple biological processes depending on their potential binding sites in human-protein coding genes and other unconventional patterns, including coding for peptides, activating Toll-like receptors as a ligand, and other manners. Accumulating evidence has demonstrated that microRNA expression is tightly regulated during phases of development, differentiation, and effector functions of immune cells, immunological disorders of systemic lupus erythematosus (SLE). This review outlines the biogenesis of miRNAs and their unconventional functions as well as underlying cellular and molecular mechanisms. It then summarizes our current knowledge about how the biogenesis of miRNAs is regulated. Moreover, an overview was provided concerning the role of abnormal expression of miRNAs in lupus immune cells. In particular, we will shed some light on the recent advances in the role of miRNAs and exosome-derived miRNAs in immunological and epigenetic pathways in the pathogenesis of SLE.

21 May 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YZYe Zhang
Ye Zhang
WLWei Liu
Wei Liu
JLJunda Lai
Junda Lai
HZHuiqiong Zeng
Huiqiong Zeng
Background: Ankylosing spondylitis (AS) is a complex condition with a significant genetic component. This study explored circulating proteins as potential genetic drug targets or biomarkers to prevent AS, addressing the need for innovative and safe treatments.Methods: We analyzed extensive data from protein quantitative trait loci (pQTLs) with up to 1,949 instrumental variables (IVs) and selected the top single-nucleotide polymorphism (SNP) associated with AS risk. Utilizing a two-sample Mendelian randomization (MR) approach, we assessed the causal relationships between identified proteins and AS risk. Colocalization analysis, functional enrichment, and construction of protein-protein interaction networks further supported these findings. We utilized phenome-wide MR (phenMR) analysis for broader validation and repurposing of drugs targeting these proteins. The Drug-Gene Interaction database (DGIdb) was employed to corroborate drug associations with potential therapeutic targets. Additionally, molecular docking (MD) techniques were applied to evaluate the interaction between target protein and four potential AS drugs identified from the DGIdb.Results: Our analysis identified 1,654 plasma proteins linked to AS, with 868 up-regulated and 786 down-regulated. 18 proteins (AGER, AIF1, ATF6B, C4A, CFB, CLIC1, COL11A2, ERAP1, HLA-DQA2, HSPA1L, IL23R, LILRB3, MAPK14, MICA, MICB, MPIG6B, TNXB, and VARS1) that show promise as therapeutic targets for AS or biomarkers, especially MAPK14, supported by evidence of colocalization. PhenMR analysis linked these proteins to AS and other diseases, while DGIdb analysis identified potential drugs related to MAPK14. MD analysis indicated strong binding affinities between MAPK14 and four potential AS drugs, suggesting effective target-drug interactions.Conclusion: This study underscores the utility of MR analysis in AS research for identifying biomarkers and therapeutic drug targets. The involvement of Th17 cell differentiation-related proteins in AS pathogenesis is particularly notable. Clinical validation and further investigation are essential for future applications.

13 September 2022 in Frontiers in Bioinformatics
Verified
Journal Article
Open access
HZHuiqiong Zeng
Huiqiong Zeng
SCShuai Chen
Shuai Chen
XLXiaoping Lu
Xiaoping Lu
ZYZhenbo Yan
Zhenbo Yan
Objective: Iguratimod (IGU) is a novel small disease-modifying compound widely used in Asia for the treatment of rheumatic diseases. IGU is a methane sulfonanilide. We applied network pharmacology to investigate the pharmacological mechanisms of IGU act on SLE.Methods: We used PharmMapper, UniProt, and OMIM databases to screen the potential targets of IGU, and the SLE-related disease targets were predicted. Hub target genes among the intersections of the potential targets (IGU) and related genes (SLE) were validated using the PPI network generated by the String database. GO and KEGG enrichment analyses were carried out using the David online platform. Finally, the molecular docking of hub targets and their corresponding compounds were completed through AutoDock Vina and PyMOL software for visualization.Result: A total of 292 potential targets of IGU, 6501 related disease targets of SLE, and 114 cross targets were screened from the aforementioned database. Network topology analysis identified 10 hub targets, such as CASP3, AKT1, EGFR, MMP9, and IGF1. GO enrichment analysis mainly focuses on the negative regulation of the apoptotic process and signal transduction. KEGG enrichment analysis illustrated that the PI3K-AKT signaling pathway, MAPK signaling pathway, and FoxO signaling pathway might play a significant role in the pharmacological mechanisms of IGU act on SLE. Molecular docking confirmed that the IGU ligand had strong binding activity to the hub targets.Conclusion: This study based on network pharmacology and molecular docking validation preliminarily revealed the protein targets affected by IGU acting on SLE through, and explored potential therapeutic mechanism role of IGU in SLE treatment by multi pathways.

22 June 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
HZHuiqiong Zeng
Huiqiong Zeng
YZYu Zhuang
Yu Zhuang
XLXiaojuan Li
Xiaojuan Li
ZYZhihua Yin
Zhihua Yin
XHXia Huang
Xia Huang
HPHaiyan Peng
Haiyan Peng
Objective: Evidences show that there may be a link between SLE and COVID-19. The purpose of this study is to screen out the diagnostic biomarkers of systemic lupus erythematosus (SLE) with COVID-19 and explore the possible related mechanisms by the bioinformatics approach.Methods: SLE and COVID-19 datasets were extracted separately from the NCBI Gene Expression Omnibus (GEO) database. The limma package in R was used to obtain the differential genes (DEGs). The protein interaction network information (PPI) and core functional modules were constructed in the STRING database using Cytoscape software. The hub genes were identified by the Cytohubba plugin, and TF-gene together with TF-miRNA regulatory networks were constructed via utilizing the Networkanalyst platform. Subsequently, we generated subject operating characteristic curves (ROC) to verify the diagnostic capabilities of these hub genes to predict the risk of SLE with COVID-19 infection. Finally, a single-sample gene set enrichment (ssGSEA) algorithm was used to analyze immune cell infiltration.Results: A total of 6 common hub genes (CDC6, PLCG1, KIF15, LCK, CDC25C, and RASGRP1) were identified with high diagnostic validity. These gene functional enrichments were mainly involved in cell cycle, and inflammation-related pathways. Compared to the healthy controls, abnormal infiltration of immune cells was found in SLE and COVID-19, and the proportion of immune cells linked to the 6 hub genes.Conclusion: Our research logically identified 6 candidate hub genes that could predict SLE complicated with COVID-19. This work provides a foothold for further study of potential pathogenesis in SLE and COVID-19.

24 June 2025 in Reproductive Sciences
Verified
Journal Article
Open access
PDF file
YZYe Zhang
Ye Zhang
ZHZhiyang Hu
Zhiyang Hu
ZCZebo Cai
Zebo Cai
JLJunda Lai
Junda Lai
HZHuiqiong Zeng
Huiqiong Zeng
Background: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder associated with chronic inflammation, insulin resistance, and ovarian dysfunction. Emerging evidence implicates granulosa cell anoikis, a specialized form of apoptosis induced by extracellular matrix detachment, in PCOS pathogenesis. However, the involvement of anoikis-related genes (ARGs) remains poorly understood. Methods: Transcriptomic data from two GEO datasets (GSE43264 and GSE98421) were integrated, followed by differential gene expression analysis and weighted gene co-expression network analysis (WGCNA). Thirteen differentially expressed ARGs (DEARGs) were identified. Functional enrichment (GO/KEGG), immune infiltration profiling (CIBERSORT), and machine learning models were used to screen for hub biomarkers. Diagnostic potential was validated using ROC and nomogram analyses. ceRNA, drug-gene, and transcription factor networks were constructed. Pancancer expression and immune relevance were assessed using TCGA, and gene function was validated through MGI. Results: Two ARGs, GSTP1 and LPCAT1, were identified as robust diagnostic markers (AUC > 0.80). These genes were significantly associated with immunosuppressive cell infiltration (e.g., elevated M2 macrophages, reduced CD8⁺ T cells). GSEA linked both genes to apoptosis, PI3K signaling, and immune pathways. MGI validation revealed that GSTP1 and LPCAT1 are involved in reproductive and metabolic regulation in murine models, supporting their functional relevance to PCOS. Drug prediction analyses identified resveratrol, curcumin, and vitamin E as potential therapeutics. Conclusion: This is the first exploratory study to identify GSTP1 and LPCAT1 as potential diagnostic biomarkers for PCOS, validated across multi-omics platforms and functional databases. These findings highlight a novel anoikis-immunity axis in PCOS and suggest new directions for biomarker-guided therapy.